SAN ANTONIO, Texas — Powerhouse Therapeutics Inc, a biotechnology company developing first-in-class cell-based therapies for treatment-resistant solid tumors, today announced that Chief Executive Officer Vincent Pham will present at BioNTX's 2025 iC³ Life Science & Healthcare Innovation Summit. The presentation will take place on Tuesday, September 16, at 3:50 PM CT during the concurrent Session 4: Company Presentations & Reverse Pitches in Dallas, Texas.
During the session, Mr. Pham will highlight the company's proprietary Immune Triad Therapy with Armed CAR T-cell Supercharger (IT-ACTS) platform and provide an update on PH102, Powerhouse's lead candidate targeting GPC3+ hepatocellular carcinoma. PH102 has demonstrated strong preclinical efficacy, including complete tumor regression in multiple standard-of-care resistant murine models of liver cancer, and represents a significant advancement in tackling one of the most treatment-resistant cancers.
“BioNTX's iC³ Summit is one of the premier gatherings of innovators, investors, and industry leaders in Texas and beyond,” said Vincent Pham, CEO of Powerhouse Therapeutics. “We are honored to be included among such a remarkable lineup of speakers and companies driving transformative progress in biotech and healthcare. This is a tremendous opportunity to share our vision and connect with partners who share our mission of delivering next-generation therapies to patients in need.”
The iC³ Summit, hosted by BioNTX, celebrates its 10th year as North Texas' flagship life science and healthcare innovation event. The conference brings together a diverse network of entrepreneurs, researchers, investors, and corporate leaders to discuss breakthrough technologies, commercialization strategies, and the future of healthcare innovation.
About Powerhouse therapeutics
Powerhouse Therapeutics Inc is a biotechnology company developing cell-based therapies that tackle treatment resistance in solid tumors and fibrotic diseases. Built on our proprietary Immune Triad Therapy with Armed CAR T-cell Supercharger (IT-ACTS) platform, we engineer multimodal living drugs that deliver targeted payloads, remodel the tumor microenvironment, and restore tissue homeostasis. Our lead candidate, PH102, is an autologous IT-ACTS therapy poised for clinical entry, with off-the-shelf and anti-fibrotic programs advancing in parallel. Founded by leading academic scientists, we combine academic rigor with translational speed to deliver paradigm-shifting therapies for all patients.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including those regarding our future results of operations and financial position, business strategy, product candidates, and planned clinical trials, are forward-looking statements. You can identify these statements by words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “potential,” “continue,” or similar expressions, as well as discussions of future events or trends.
Forward-looking statements are subject to many risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, delays or failures in product development, clinical-trial outcomes that differ from preclinical data, adverse decisions by regulatory authorities, challenges in manufacturing or supply chains, our ability to secure and protect intellectual-property rights, competition in the marketplace, changes in healthcare regulations, and our need for additional financing. More information about these and other risks is included in our filings with the U.S. Securities and Exchange Commission.
We caution readers not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Powerhouse Therapeutics Inc undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or circumstances, except as required by law.
